Physician profile
Christy L Davis
NPI 1063662419
$208,405.04
in general payments reported to CMS, 2019-2025
52 companies · $44K in 2025
The $44K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,320 · 2022: $64K · 2023: $71K · 2024: $26K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Travel and Lodging: $24K · Honoraria: $17K · Food and Beverage: $15K · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,983.38 |
| Travel and Lodging | $23,631.66 |
| Honoraria | $17,040.00 |
| Food and Beverage | $14,529.83 |
| Education | $156.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $164,066.02 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Rhythm Pharmaceuticals, INC. | $29,163.94 | 2022-2024 | Imcivree, Imcivree |
| Lilly USA, LLC | $2,444.42 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $2,123.91 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $1,295.25 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $1,235.69 | 2021-2025 | |
| Corcept Therapeutics | $833.53 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.02 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Alexion Pharmaceuticals, INC. | $642.50 | 2021-2024 | Strensiq |
| Dexcom, INC. | $590.66 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $453.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $414.81 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $406.08 | 2021-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $351.62 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $333.22 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $322.38 | 2021-2025 | Minimed 780g |
| Regeneron Healthcare Solutions, INC. | $258.46 | 2021-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals Lp | $253.64 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $242.37 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $169.76 | 2022-2025 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $165.80 | 2023-2024 | Crysvita |
| Esperion Therapeutics, INC. | $153.47 | 2021-2025 | Nexletol |
| Grt US Holding, INC. | $150.03 | 2021-2022 | |
| Insulet Corporation | $120.82 | 2021-2025 | Omnipod |
| Pfizer INC. | $100.62 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $99.56 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.55 | 2021 | |
| Tolmar, INC. | $83.33 | 2024-2025 | Jatenzo |
| Averitas Pharma INC. | $80.39 | 2023-2025 | Qutenza |
| Ucb, INC. | $75.79 | 2023 | |
| Radius Health, INC. | $71.47 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $70.70 | 2021 | |
| Neurocrine Biosciences, INC. | $68.37 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $65.90 | 2025 | Tryngolza |
| Merck Sharp & Dohme LLC | $63.77 | 2021 | |
| Horizon Therapeutics Plc | $58.56 | 2022-2023 | Tepezza |
| Acella Pharmaceuticals, LLC | $56.69 | 2024-2025 | NP Thyroid 60 |
| Axsome Therapeutics, INC. | $56.25 | 2025 | Auvelity, Sunosi |
| Lifescan, INC. | $45.89 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $45.26 | 2021-2025 | Provenge |
| Eusa Pharma (US) LLC | $42.71 | 2022 | |
| Ibsa Pharma INC. | $34.42 | 2022-2023 | Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $33.05 | 2021-2025 | |
| Boston Scientific Corporation | $30.56 | 2021-2022 | |
| Stryker Corporation | $23.75 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Embecta Corp. | $22.53 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $21.72 | 2025 | Twiist |
| Regeneron Pharmaceuticals, INC. | $19.97 | 2025 | Evkeeza |
| Amryt Pharma Holdings Ltd | $18.22 | 2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $16.10 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.